Visit coronavirus.gov for the latest Coronavirus Disease (COVID-19) updates.

You are here

HDS-15.2 Data Details

Expand All

HDS-15.2 Increase aspirin use as recommended among men aged 45 to 79 years with no history of cardiovascular disease

About the Data

Description of the data source, numerator, denominator, survey questions, and other relevant details about the national estimate.

Data Source: 
National Ambulatory Medical Care Survey
Changed Since the Healthy People 2020 Launch: 
Yes
Measure: 
percent
Baseline (Year): 
15.9 (2006–07)
Target: 
19.5
Target-Setting Method: 
Minimal statistical significance
Target-Setting Method Justification: 
The target is the smallest improvement that results in a statistically significant difference when tested against the baseline value, assuming the same standard error for the target as the baseline.
Numerator: 

Number of visits by men aged 45 to 79 years with no history of cardiovascular disease (ICD-9-CM codes 410-414, 429.2, 433-438, 440.1, 440.2, 444, 445, V12.54, V45.81, and V45.82) to non-Federal physicians in office-based practices where aspirin or other antiplatelet medication was ordered, supplied, administered, or continued.

Denominator: 

Number of visits by men aged 45 to 79 years with no history of cardiovascular disease to non-Federal physicians in office-based practices.

Comparable Healthy People 2010 Objective: 
Not applicable
Questions Used to Obtain the National Baseline Data: 

    From the 2006 and 2007 National Ambulatory Medical Care Survey patient record:

    [NUMERATOR:]

    Include Rx and OTC drugs, immunizations, allergy shots, anesthetics, chemotherapy, and dietary supplements that were ordered, supplied, administered or continued during the visit.

    [NUMERATOR AND DENOMINATOR:]

    (Question 5a) As specifically as possible, list diagnoses related to this visit including chronic conditions.

    1. Primary Diagnosis:_______________
    2. Other: _______________
    3. Other: _______________
Data Collection Frequency: 
Annual
Methodology Notes: 

    The primary objective of this analysis was to estimate the prevalence of physician-prescribed aspirin and other antiplatelet medications among men aged 45 to 79 years with no history of cardiovascular disease as recommended by the U.S. Preventive Services Task Force and other major guidelines. Visits for pre- or postsurgery follow-up, patients with documented contraindications to chronic aspirin use (coagulation defects, purpura and other hemorrhagic conditions, subarachnoid hemorrhage, intracerebral hemorrhage, acute hepatic failure, and gastrointestinal hemorrhage), and persons prescribed anticoagulant medication (warfarin, heparin, or low molecular weight heparins) were excluded from this analysis of patients. The unit of analysis for NAMCS is the patient visit.

Revision History

Any change to the objective text, baseline, target, target-setting method or data source since the Healthy People 2020 launch.

Description of Changes Since the Healthy People 2020 Launch: 
In 2015, this objective became measurable. In 2017, the baseline was revised from 15.8 to 15.9 by excluding data from community health centers from the analysis for comparability with the 2012-2013 dataset which did not include data from community health centers. The target was adjusted from 19.3 to 19.5 to reflect the revised baseline using the original target-setting method.

References

Additional resources about the objective

  1. George MG, Tong X, Sonnenfeld N, Hong Y. Recommended use of aspirin and other antiplatelet medications among adults--National Ambulatory Medical Care Survey and National Hospital Ambulatory Medical Care Survey, United States, 2005-2008. MMWR Morb Mortal Wkly Rep. 2012 Jun 15;61 Suppl:11-8.